These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 22679900)

  • 1. Administration of angiotensin receptor II blockade improves vascular function, urinary albumin excretion, and left ventricular hypertrophy in low-risk essential hypertensive patients receiving antihypertensive treatment with calcium channel blockers.
    Watanabe Y; Kikuchi T; Mitsuhashi T; Kimura H; Tsuchida Y; Otsuka K
    Clin Exp Hypertens; 2013; 35(2):87-94. PubMed ID: 22679900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Administration of an angiotensin-converting enzyme inhibitor improves vascular function and urinary albumin excretion in low-risk essential hypertensive patients receiving anti-hypertensive treatment with calcium channel blockers. Organ-protecting effects independent of anti-hypertensive effect.
    Watanabe Y; Takasugi E; Shitakura K; Okajima K; Hota N; Kubo Y; Nunoda S; Otsuka K
    Clin Exp Hypertens; 2011; 33(4):246-54. PubMed ID: 21699451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective effects of an angiotensin II receptor blocker and a long-acting calcium channel blocker against cardiovascular organ injuries in hypertensive patients.
    Ishimitsu T; Kobayashi T; Honda T; Takahashi M; Minami J; Ohta S; Inada H; Yoshii M; Ono H; Matsuoka H
    Hypertens Res; 2005 Apr; 28(4):351-9. PubMed ID: 16138566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of telmisartan on arterial stiffness assessed by the cardio-ankle vascular index in hypertensive patients.
    Kinouchi K; Ichihara A; Sakoda M; Kurauchi-Mito A; Murohashi-Bokuda K; Itoh H
    Kidney Blood Press Res; 2010; 33(4):304-12. PubMed ID: 20664284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal and vascular protective effects of telmisartan in patients with essential hypertension.
    Morimoto S; Yano Y; Maki K; Sawada K
    Hypertens Res; 2006 Aug; 29(8):567-72. PubMed ID: 17137211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination therapy of angiotensin II receptor blocker and calcium channel blocker exerts pleiotropic therapeutic effects in addition to blood pressure lowering: amlodipine and candesartan trial in Yokohama (ACTY).
    Maeda A; Tamura K; Kanaoka T; Ohsawa M; Haku S; Azushima K; Dejima T; Wakui H; Yanagi M; Okano Y; Fujikawa T; Toya Y; Mizushima S; Tochikubo O; Umemura S
    Clin Exp Hypertens; 2012; 34(4):249-57. PubMed ID: 22571446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin II receptor blocker and long-acting calcium channel blocker combination therapy decreases urinary albumin excretion while maintaining glomerular filtration rate.
    Nakagawa N; Fujino T; Kabara M; Matsuki M; Chinda J; Kikuchi K; Hasebe N;
    Hypertens Res; 2011 Oct; 34(10):1121-6. PubMed ID: 21796123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction (TELMAR) as assessed by magnetic resonance imaging in patients with mild-to-moderate hypertension--a prospective, randomised, double-blind comparison of telmisartan with metoprolol over a period of six months rationale and study design.
    Friedrich MG; Dahlöf B; Sechtem U; Unger T; Knecht M; Dietz R;
    J Renin Angiotensin Aldosterone Syst; 2003 Dec; 4(4):234-43. PubMed ID: 14689371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Left ventricular (LV) geometry and dipping state are determinants of LV mass reduction with angiotensin-converting enzyme inhibitor antihypertensive treatment.
    Aznaouridis KA; Vyssoulis GP; Karpanou EA; Marinakis AG; Barbetseas JD; Zervoudaki AI; Cokkinos DV; Stefanadis CI
    Blood Press Monit; 2007 Apr; 12(2):87-94. PubMed ID: 17353651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Titration of telmisartan, but not addition of amlodipine, reduces urine albumin in diabetic patients treated with telmisartan-diuretic.
    Kojima M; Ohashi M; Dohi Y; Kimura G
    J Hypertens; 2013 Jan; 31(1):186-91. PubMed ID: 23047595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beneficial effects of combination therapy with angiotensin II receptor blocker and angiotensin-converting enzyme inhibitor on vascular endothelial function.
    Morimoto S; Maki K; Aota Y; Sakuma T; Iwasaka T
    Hypertens Res; 2008 Aug; 31(8):1603-10. PubMed ID: 18971536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renoprotective effect and cost-effectiveness of using benidipine, a calcium channel blocker, to lower the dose of angiotensin receptor blocker in hypertensive patients with albuminuria.
    Saito F; Fujita H; Takahashi A; Ichiyama I; Harasawa S; Oiwa K; Takahashi N; Otsuka Y; Uchiyama T; Kanmatsuse K; Kushiro T
    Hypertens Res; 2007 Jan; 30(1):39-47. PubMed ID: 17460370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of telmisartan-amlodipine combination at different doses on urinary albumin excretion in hypertensive diabetic patients with microalbuminuria.
    Fogari R; Derosa G; Zoppi A; Preti P; Lazzari P; Destro M; Fogari E; Rinaldi A; Mugellini A
    Am J Hypertens; 2007 Apr; 20(4):417-22. PubMed ID: 17386350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of simvastatin on left ventricular hypertrophy and left ventricular function in patients with essential hypertension.
    Pan XD; Zeng ZH; Liang LY; Luo JD; Xiao AY; Lai Q; Wen YH; Lu DF; Wang W; He ZC; He WK
    Clin Exp Hypertens; 2011; 33(8):558-64. PubMed ID: 21957976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the angiotensin II type 1 receptor antagonist candesartan, compared with angiotensin-converting enzyme inhibitors, on the urinary excretion of albumin and type IV collagen in patients with diabetic nephropathy.
    Sato A; Tabata M; Hayashi K; Saruta T
    Clin Exp Nephrol; 2003 Sep; 7(3):215-20. PubMed ID: 14586718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension.
    Ishimitsu T; Numabe A; Masuda T; Akabane T; Okamura A; Minami J; Matsuoka H
    Hypertens Res; 2009 Nov; 32(11):962-8. PubMed ID: 19696778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of fixed dose combination (FDC) of telmisartan+ramipril usage in patients with micro-albuminuria and persistent hypertension: A TRIUMPH study.
    Sharma A; Baliga V;
    J Indian Med Assoc; 2008 Mar; 106(3):191-4, 196. PubMed ID: 18712142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular effects of a low-dose combination of ramipril and felodipine in spontaneously hypertensive rats.
    Mervaala EM; Teräväinen TL; Malmberg L; Laakso J; Vapaatalo H; Karppanen H
    Br J Pharmacol; 1997 Jun; 121(3):503-10. PubMed ID: 9179393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Improved protection of heart and kidneys in the hypertensive patient. ACE inhibitor and AT1 blocker combined?].
    MMW Fortschr Med; 2003 Jun; 145(23):59. PubMed ID: 12854231
    [No Abstract]   [Full Text] [Related]  

  • 20. ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial.
    Ogihara T; Fujimoto A; Nakao K; Saruta T;
    Expert Rev Cardiovasc Ther; 2008 Oct; 6(9):1195-201. PubMed ID: 18939907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.